Abstract:Reducing sugars and reactive aldehydes, such as glyceraldehyde, non-enzymatically react with amino or guanidino groups of proteins to form advanced glycation end-products (AGEs) by the Maillard reaction that involves Schiff base formation followed by Amadori rearrangement. AGEs are found relatively in abundance in the human eye and to accumulate at a higher rate in diseases that impair vision such as cataract, diabetic retinopathy or age-related macular degeneration. We identified two novel AGEs of pyrrolopyri… Show more
“…To date, the following GA-AGE structures have been detected: triosidines [41], GLAP [42], PPGs [43], MG-H1 [44], and ArgP [45] (Figures 1 and 2). Trihydroxy-triosidine, GLAP, and PPGs were identified in the Lys residues and MG-H1 and ArgP in the Arg residues of proteins.…”
Section: Structures Of Ga-agesmentioning
confidence: 99%
“…The pyridinium-type AGEs trihydroxy-triosidine and GLAP have been identified as GA-AGEs; however, their pathological effects are yet to be clarified. The Maillard reaction between N α -acetyl-L-Lys and GA was recently examined under physiological conditions and the main products identified were PPG1 and PPG2, which are fluorescent AGEs in which pyrrolopyridine ring structures cross-link two Lys molecules [43]. Based on these findings, a mechanism was proposed for the generation of PPG1 and PPG2 in vitro via a unique reaction to expand the skeleton as an alternative to the typical route for the formation of Schiff bases.…”
Section: Ppgsmentioning
confidence: 99%
“…However, this protective effect was not observed when antibodies targeting other types of AGEs were used. Therefore, AGE structures containing epitopes recognized by the anti-GA-AGE antibody solely appear to be toxic, are called toxic AGEs (TAGE), and are distinct from other GA-AGEs, including triosidines [41], GA-derived pyridinium compounds (GLAP) [42], pyrrolopyridinium Lys dimers derived from GA (PPGs) [43], methylglyoxal (MGO)-derived hydroimidazolone 1 (MG-H1) [44], and argpyrimidine (ArgP) [45].…”
Advanced glycation end-products (AGEs) have recently been implicated in the onset/progression of lifestyle-related diseases (LSRDs); therefore, the suppression of AGE-induced effects may be used in both the prevention and treatment of these diseases. Various AGEs are produced by different biological pathways in the body. Glyceraldehyde (GA) is an intermediate of glucose and fructose metabolism, and GA-derived AGEs (GA-AGEs), cytotoxic compounds that accumulate and induce damage in mammalian cells, contribute to the onset/progression of LSRDs. The following GA-AGE structures have been detected to date: triosidines, GA-derived pyridinium compounds, GA-derived pyrrolopyridinium lysine dimers, methylglyoxal-derived hydroimidazolone 1, and argpyrimidine. GA-AGEs are a key contributor to the formation of toxic AGEs (TAGE) in many cells. The extracellular leakage of TAGE affects the surrounding cells via interactions with the receptor for AGEs. Elevated serum levels of TAGE, which trigger different types of cell damage, may be used as a novel biomarker for the prevention and early diagnosis of LSRDs as well as in evaluations of treatment efficacy. This review provides an overview of the structures of GA-AGEs.
“…To date, the following GA-AGE structures have been detected: triosidines [41], GLAP [42], PPGs [43], MG-H1 [44], and ArgP [45] (Figures 1 and 2). Trihydroxy-triosidine, GLAP, and PPGs were identified in the Lys residues and MG-H1 and ArgP in the Arg residues of proteins.…”
Section: Structures Of Ga-agesmentioning
confidence: 99%
“…The pyridinium-type AGEs trihydroxy-triosidine and GLAP have been identified as GA-AGEs; however, their pathological effects are yet to be clarified. The Maillard reaction between N α -acetyl-L-Lys and GA was recently examined under physiological conditions and the main products identified were PPG1 and PPG2, which are fluorescent AGEs in which pyrrolopyridine ring structures cross-link two Lys molecules [43]. Based on these findings, a mechanism was proposed for the generation of PPG1 and PPG2 in vitro via a unique reaction to expand the skeleton as an alternative to the typical route for the formation of Schiff bases.…”
Section: Ppgsmentioning
confidence: 99%
“…However, this protective effect was not observed when antibodies targeting other types of AGEs were used. Therefore, AGE structures containing epitopes recognized by the anti-GA-AGE antibody solely appear to be toxic, are called toxic AGEs (TAGE), and are distinct from other GA-AGEs, including triosidines [41], GA-derived pyridinium compounds (GLAP) [42], pyrrolopyridinium Lys dimers derived from GA (PPGs) [43], methylglyoxal (MGO)-derived hydroimidazolone 1 (MG-H1) [44], and argpyrimidine (ArgP) [45].…”
Advanced glycation end-products (AGEs) have recently been implicated in the onset/progression of lifestyle-related diseases (LSRDs); therefore, the suppression of AGE-induced effects may be used in both the prevention and treatment of these diseases. Various AGEs are produced by different biological pathways in the body. Glyceraldehyde (GA) is an intermediate of glucose and fructose metabolism, and GA-derived AGEs (GA-AGEs), cytotoxic compounds that accumulate and induce damage in mammalian cells, contribute to the onset/progression of LSRDs. The following GA-AGE structures have been detected to date: triosidines, GA-derived pyridinium compounds, GA-derived pyrrolopyridinium lysine dimers, methylglyoxal-derived hydroimidazolone 1, and argpyrimidine. GA-AGEs are a key contributor to the formation of toxic AGEs (TAGE) in many cells. The extracellular leakage of TAGE affects the surrounding cells via interactions with the receptor for AGEs. Elevated serum levels of TAGE, which trigger different types of cell damage, may be used as a novel biomarker for the prevention and early diagnosis of LSRDs as well as in evaluations of treatment efficacy. This review provides an overview of the structures of GA-AGEs.
“…However, this study revealed that argpyrimidine and MG-H1 were generated from glyceraldehyde in PANC-1 and HPDE cells. Finally, other structures of GA-AGEs (unidentified in the cell) [1,110,111] could be included in the modification data, identified, and quantified.…”
Section: Comparison With Maldi-ms and Lc-esi-msmentioning
Various types of advanced glycation end-products (AGEs) have been identified and studied. I have reported a novel slot blot analysis to quantify two types of AGEs, glyceraldehyde-derived AGEs, also called toxic AGEs (TAGE), and 1,5-anhydro-D-fructose AGEs. The traditional slot blot method has been used for the detection and quantification of RNA, DNA, and proteins since around 1980 and is one of the more commonly used analog technologies to date. However, the novel slot blot analysis has been used to quantify AGEs from 2017 to 2022. Its characteristics include (i) use of a lysis buffer containing tris-(hydroxymethyl)-aminomethane, urea, thiourea, and 3-[3-(cholamidopropyl)-dimetyl-ammonio]-1-propane sulfonate (a lysis buffer with a composition similar to that used in two-dimensional gel electrophoresis-based proteomics analysis); (ii) probing of AGE-modified bovine serum albumin (e.g., standard AGE aliquots); and (iii) use of polyvinylidene difluoride membranes. In this review, the previously used quantification methods of slot blot, western blot, immunostaining, enzyme-linked immunosorbent assay, gas chromatography–mass spectrometry (MS), matrix-associated laser desorption/ionization–MS, and liquid chromatography–electrospray ionization–MS are described. Lastly, the advantages and disadvantages of the novel slot blot compared to the above methods are discussed.
Cardiomyocyte dysfunction and cardiovascular diseases (CVDs) can be classified as ischemic or non-ischemic. We consider the induction of cardiac tissue dysfunction by intracellular advanced glycation end-products (AGEs) in cardiomyocytes as a novel type of non-ischemic CVD. Various types of AGEs can be generated from saccharides (glucose and fructose) and their intermediate/non-enzymatic reaction byproducts. Recently, certain types of AGEs (Nε-carboxymethyl-lycine [CML], 2-ammnonio-6-[4-(hydroxymetyl)-3-oxidopyridinium-1-yl]-hexanoate-lysine [4-hydroxymethyl-OP-lysine, hydroxymethyl-OP-lysine], and Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [MG-H1]) were identified and quantified in the ryanodine receptor 2 (RyR2) and F-actin–tropomyosin filament in the cardiomyocytes of mice or patients with diabetes and/or heart failure. Under these conditions, the excessive leakage of Ca2+ from glycated RyR2 and reduced contractile force from glycated F-actin–tropomyosin filaments induce cardiomyocyte dysfunction. CVDs are included in lifestyle-related diseases (LSRDs), which ancient people recognized and prevented using traditional medicines (e.g., Kampo medicines). Various natural compounds, such as quercetin, curcumin, and epigallocatechin-3-gallate, in these drugs can inhibit the generation of intracellular AGEs through mechanisms such as the carbonyl trap effect and glyoxalase 1 activation, potentially preventing CVDs caused by intracellular AGEs, such as CML, hydroxymethyl-OP, and MG-H1. These investigations showed that bioactive herbal extracts obtained from traditional medicine treatments may contain compounds that prevent CVDs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.